The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ...
Climate Compass on MSN
11 times science sounded like sci-fi - until it wasn't
Personalized Gene Editing Saves Baby in Record Time In early 2025, researchers successfully treated a baby boy with a rare, ...
Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of CRISPR advances is not only correcting single mutations in the lab but ...
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
A study that will deliver CRISPR gene editing technology directly into cancer cells in patients’ bodies is preparing to seek regulatory approval from the FDA, STAT reports. The study, proposed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results